@article {Finneran2019.12.11.19014399, author = {Phoebe A Finneran and Tinamarie Sanborn and Xiao Guo and Kate C Traynor and Michael R. Jaff and Pradeep Natarajan}, title = {Assessment and Utilization of Patient-Reported Outcomes Measures to Improve Cardiovascular Disease Prevention}, elocation-id = {2019.12.11.19014399}, year = {2019}, doi = {10.1101/2019.12.11.19014399}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The American Heart Association{\textquoteright}s Life{\textquoteright}s Simple 7 (LS7) consist of clinical factors and health-related behaviors associated with cardiovascular health. The prevalence of these health factors among patients seeking specialized cardiovascular care is unknown. We sought to quantify patient-reported cardiovascular risk among those seeking specialized cardiovascular care and implement tailored quality improvement interventions.Methods and Results Patients cared for by cardiovascular specialists at an academic medical center were surveyed with a modified LS7. We compared the prevalence of optimal health factors by atherosclerotic cardiovascular disease (ASCVD) status. Recent smokers or patients with ASCVD reporting non-adherence to antiplatelets/statins were contacted.Surveys for 5,950 patients were collected during 2014 to 2016. The mean (SD) age was 64 (15) years, 2613 (44\%) were women, and 3478 (58\%) had ASCVD. Only 34 (0.6 \%) achieved ideal status for all 7 factors, which did not differ by ASCVD status (P=0.48). Of 404 (6.8\%) reporting recent smoking, 94/404 (23.3\%) were successfully contacted, and 71/404 (17.6\%) accepted support. Among those with ASCVD, 84 (2.4\%) reported not taking a statin or antiplatelet without contraindications.Conclusions The prevalence of optimal health factors, including health-related behaviors, among patients cared for by cardiovascular specialists remains low. Assessment of patient-reported outcomes facilitates scalable interventions to improve cardiovascular disease prevention.Competing Interest StatementP.N. reports consulting income from Apple and research grants from Boston Scientific, Amgen, and Apple. All other co-authors do not report any relevant conflicts of interests.Funding StatementThis work was supported by Massachusetts General Hospital. P.N. is supported by a grant from the National Heart Lung and Blood Institute (K08 HL140203) and Hassenfeld Scholar award from the Massachusetts General Hospital.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not available. Data was collected at Massachusetts General Hospital as a part of a quality improvement initiative and cannot be shared outside the institution.}, URL = {https://www.medrxiv.org/content/early/2019/12/14/2019.12.11.19014399}, eprint = {https://www.medrxiv.org/content/early/2019/12/14/2019.12.11.19014399.full.pdf}, journal = {medRxiv} }